DRUG METABOLISM AND DISPOSITION
Scope & Guideline
Exploring the Frontiers of Pharmacology
Introduction
Aims and Scopes
- Pharmacokinetics and Drug Disposition:
Research articles often explore the pharmacokinetics of drugs, including absorption, distribution, metabolism, and excretion (ADME). This encompasses both in vivo and in vitro studies, utilizing physiologically based pharmacokinetic modeling to predict human responses. - Drug-Metabolizing Enzymes:
A key focus is on cytochrome P450 enzymes and other drug-metabolizing enzymes, examining their roles in drug metabolism, genetic polymorphisms, and variations in enzymatic activity across different populations. - Transport Mechanisms:
The journal highlights studies on drug transporters, including their regulation, function, and impact on drug absorption and disposition, emphasizing the interplay between metabolic enzymes and transport systems. - Toxicology and Drug Safety:
Research often addresses the toxicological aspects of drug metabolism, including the identification of metabolites that may contribute to adverse drug reactions and strategies for mitigating these effects. - Clinical Relevance and Biomarkers:
The journal emphasizes the clinical implications of drug metabolism research, including the identification of biomarkers for drug efficacy and safety, and the impact of genetic and environmental factors on individual drug responses. - Innovative Methodologies:
The use of novel experimental approaches, such as high-throughput screening, advanced analytical techniques, and computational modeling, is frequently reported to enhance our understanding of drug metabolism and disposition.
Trending and Emerging
- Precision Medicine and Pharmacogenomics:
There is an increasing emphasis on precision medicine and pharmacogenomics, as studies investigate how genetic variations affect drug metabolism, efficacy, and safety, paving the way for individualized therapeutic strategies. - Physiologically Based Pharmacokinetic (PBPK) Modeling:
The use of PBPK modeling is on the rise, allowing for more accurate predictions of drug behavior in humans based on in vitro data, enhancing the relevance of preclinical studies to clinical outcomes. - Gut Microbiome Interactions:
Emerging research on the role of the gut microbiome in drug metabolism is gaining traction, highlighting how microbial metabolites can influence drug efficacy and toxicity. - Transporter Biology and Drug Disposition:
There is a growing focus on the roles of transporters in drug absorption and disposition, particularly how they interact with metabolic enzymes and their implications for drug-drug interactions. - Innovative Drug Delivery Systems:
Research into novel drug delivery systems, such as nanoparticles and liposomal formulations, is trending, reflecting a broader interest in optimizing drug bioavailability and therapeutic outcomes. - Environmental and Dietary Influences:
Recent studies are increasingly examining how environmental factors and dietary components affect drug metabolism, emphasizing the importance of lifestyle in pharmacokinetic profiles.
Declining or Waning
- Traditional In Vitro Models:
There seems to be a waning interest in conventional in vitro models for drug metabolism, such as using only liver microsomes or hepatocytes, as researchers increasingly adopt more sophisticated systems like 3D cell cultures or organ-on-chip technologies. - Non-Cytochrome P450 Enzyme Studies:
Research specifically focused on non-cytochrome P450 enzymes appears to be less frequent, suggesting a shift towards more detailed investigations of cytochrome P450 enzymes and their interactions with other metabolic pathways. - General Drug Interaction Studies:
There is a noticeable decline in the publication of generic drug-drug interaction studies without a specific focus on mechanisms, as the field moves towards more nuanced explorations of specific pathways and genetic influences. - Animal Models for Drug Metabolism:
The reliance on traditional animal models for drug metabolism studies is decreasing, with a growing emphasis on humanized models and in vitro systems that better predict human responses. - Historical Perspectives:
Papers providing broad historical overviews on drug metabolism topics are becoming less common, indicating a shift towards more focused, cutting-edge research that addresses current challenges in drug metabolism and pharmacokinetics.
Similar Journals
Clinical Pharmacology in Drug Development
Innovating therapeutics through rigorous research.Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.
PHARMAZIE
Bridging research and practice in pharmacology.PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.
Advances in Pharmacological and Pharmaceutical Sciences
Exploring Innovations in Pharmaceutical Research.Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.
PHARMACEUTICAL RESEARCH
Elevating the standards of drug development with cutting-edge studies.PHARMACEUTICAL RESEARCH, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the ever-evolving field of pharmaceutical sciences. With an ISSN of 0724-8741 and an E-ISSN of 1573-904X, this journal has established itself as a critical hub for disseminating innovative research from 1984 to 2024. The journal holds impressive rankings in prominent categories, including Q2 in Biotechnology and Q2 in Pharmaceutical Science, reflecting its robust impact on the global scientific community. The journal aims to provide researchers, professionals, and students with high-quality articles that contribute significantly to the advancement of drug development and medicinal applications. Although it does not currently offer Open Access options, its rigorous peer-review process ensures that only the highest caliber research is published, making it a valuable resource for those seeking to stay at the forefront of pharmaceutical innovation.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Pioneering Discoveries in Pharmacology and PhysiologyCLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.
ADMET and DMPK
Innovating pharmacokinetics for a healthier world.ADMET and DMPK is a premier open-access journal published by IAPC PUBLISHING since 2013, focusing on the rapidly evolving fields of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK (Drug Metabolism and Pharmacokinetics). Catering to researchers, professionals, and students in the realms of pharmacology, toxicology, and medicinal chemistry, this journal plays a crucial role in fostering innovation and collaboration within the interdisciplinary landscape of drug development. With an impressive Q1 ranking in Pharmacology, Toxicology and Pharmaceutics and ranking in the top percentiles across various categories such as Chemistry and Health, ADMET and DMPK provides a reputable platform for high-quality publications. Its global reach, complemented by its open-access model, ensures that valuable research is accessible to a wide audience. As we converge towards 2024, this journal remains dedicated to advancing knowledge and practices that shape the future of drug discovery and safety, making it an essential resource in the scientific community.
International Journal of Pharmacology
Championing Knowledge in Pharmacology and PharmaceuticsWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
Pioneering Research for Tomorrow's TherapeuticsASSAY AND DRUG DEVELOPMENT TECHNOLOGIES is a peer-reviewed journal published by Mary Ann Liebert, Inc., focused on the innovative fields of pharmacology and drug development. With its ISSN 1540-658X and E-ISSN 1557-8127, the journal has successfully contributed to the scientific community since its inception in 2002, converging into one comprehensive resource by 2024. Positioned in the Q3 quartile for Drug Discovery and Q4 for Molecular Medicine as per the 2023 rankings, the journal is dedicated to disseminating cutting-edge research that addresses the complexities of drug assay techniques and their implications in therapeutics. Although currently not an open-access publication, it offers significant insights and findings valuable to researchers, professionals, and students in the realm of biochemistry and pharmacology. With a commitment to advancing knowledge and innovation, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES continues to be an essential platform for the latest advancements in drug discovery and development.
DRUGS IN R&D
Connecting researchers for a healthier tomorrow.DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.
Drug Metabolism and Pharmacokinetics
Unlocking the Secrets of Xenobiotic ProcessesDrug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.